| 6 0.1 (1.69%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.24 | 1-year : | 7.6 |
| Resists | First : | 6.2 | Second : | 6.5 |
| Pivot price | 5.9  |
|||
| Supports | First : | 5.71 | Second : | 4.75 |
| MAs | MA(5) : | 5.88  |
MA(20) : | 5.98 |
| MA(100) : | 6.14 |
MA(250) : | 6.07 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 23.1 |
D(3) : | 17.4 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 7.3 | Low : | 4.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRPO ] has closed below upper band by 20.3%. Bollinger Bands are 65.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.01 - 6.03 | 6.03 - 6.05 |
| Low: | 5.75 - 5.78 | 5.78 - 5.8 |
| Close: | 5.95 - 6 | 6 - 6.04 |
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Wed, 20 Nov 2024
Precipio Inc (PRPO) Q3 2024 Earnings Call Highlights: Strong Growth in Diagnostic Services and ... - Yahoo Finance
Tue, 12 Nov 2024
Precipio director Richard Sandberg sells $12,558 in stock - Investing.com
Sat, 09 Nov 2024
Precipio (NASDAQ: PRPO) to Host Q3-2024 Shareholder Update Call - Defense World
Thu, 07 Nov 2024
Precipio to Host Q3-2024 Shareholder Update Call - TipRanks
Wed, 06 Nov 2024
Precipio (PRPO) Sets Q3 2024 Earnings Call: Cancer Diagnostics Update Coming Nov 18 - StockTitan
Sat, 07 Sep 2024
Precipio Incentivizes Staff with Strategic Stock Option Repricing - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 12.9 (%) |
| Held by Institutions | 8.7 (%) |
| Shares Short | 5 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -1.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.15 |
| Profit Margin | -22.9 % |
| Operating Margin | -27.3 % |
| Return on Assets (ttm) | -19 % |
| Return on Equity (ttm) | -29.3 % |
| Qtrly Rev. Growth | 25.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 11.29 |
| EBITDA (p.s.) | -2.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | -1 (M) |
| PE Ratio | -3.32 |
| PEG Ratio | 0 |
| Price to Book value | 0.59 |
| Price to Sales | 0.53 |
| Price to Cash Flow | -9.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|